MAPT and Mental deterioration: Moreover, our work underlines the utility of tau PET imaging for early identification of patients at risk of cognitive decline in the AD spectrum, which would enable accurate prognosis in a clinical setting and inclusion of appropriate participants in anti-AD clinical trials.